by Market Overview:
Scopolamine is an anticholinergic and antimuscarinic alkaloid extracted from plants of the nightshade family. It is widely used to treat motion sickness and postoperative nausea and vomiting. The pharmaceutical properties of scopolamine make it useful in alleviating nausea, dizziness, and vomiting.
Market key trends:
One of the key trend in the Scopolamine market is growing demand for antiemetic drugs. Antiemetic drugs are used to prevent or treat nausea and vomiting. Scopolamine is an effective anticholinergic antiemetic drug that provides relief from nausea, vomiting and dizziness associated with motion sickness. Rising prevalence of nausea and vomiting is fueling the growth of antiemetic drugs market. According to WHO, around 30% of general population experiences motion sickness. Increasing sea travels, road travels, and space travels have led to growing demand for motion sickness relieving drugs like Scopolamine.
The scopolamine market has been witnessing increased adoption of transdermal patches and gums. Scopolamine patches and gums deliver a continuous dose of scopolamine through the skin or buccal mucosa into the systemic circulation, thus providing an extended duration of action ranging from 3 to 4 days. These delivery forms help prevent motion sickness for an extended period through a single application and improve patient compliance compared to traditional oral tablets.
The global Scopolamine Market Share is estimated to be valued at US$ 3676.85 Bn in 2023 and is expected to exhibit a CAGR of 4.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
SWOT Analysis
Strengths: Continuous and extended delivery of medication for up to 4 days through transdermal patches and gums leads to better management of motion sickness. Several generic manufacturers offering affordable treatment options.
Weaknesses: Side effects with overdose such as blurred vision, dilated pupils, dry mouth, difficult urination, and flushing. Scopolamine patches can cause skin irritation in some patients.
Opportunities: Growth opportunities in emerging markets of Asia Pacific and Latin America due to increasing sea/road travel and cruise trips. New product development for pediatric population.
Threats: Availability of various alternative motion sickness medications such as antihistamines. Patent expiries of major companies’ blockbuster drugs leading to price erosion.
Key Takeaways
The global scopolamine market size was valued at US$ 3,676.85 billion in 2023 and is expected to reach US$ 5,124.32 billion by 2030, expanding at a CAGR of 4.8% during the forecast period. Increased sea/road travels and ocean cruises in regions such as Asia Pacific and South America are contributing to demand growth.
Regional analysis: The Asia Pacific region dominated the global market in 2023 and is projected to witness the highest growth during the forecast period. Rapid economic development and growth of the middle-class population in countries such as China and India have boosted travel and tourism activities in the region.
Key players: Major players operating in the scopolamine market include Baxter International Inc., GlaxoSmithKline plc, Novartis AG, Perrigo Company plc, Caleb Pharmaceuticals, Inc., Myungmoon Pharma Co. LTD., Alchem International, Phytex Australia, Centroflora-Cms, Alkaloids of Australia, and Fine Chemicals Corporation. These players are focused on new product approvals and launches to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
